ACLAX
Price
$16.52
Change
+$0.11 (+0.67%)
Updated
Jul 10 closing price
Net Assets
5.68B
MVCAX
Price
$34.02
Change
+$0.11 (+0.32%)
Updated
Jul 10 closing price
Net Assets
17.25B
Interact to see
Advertisement

ACLAX vs MVCAX

ACLAX vs MVCAX Comparison Chart in %
View a ticker or compare two or three
VS
ACLAX vs. MVCAX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLAX is a StrongBuy and MVCAX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
MVCAX has more cash in the bank: 17.2B vs. ACLAX (5.68B). ACLAX pays higher dividends than MVCAX: ACLAX (1.22) vs MVCAX (1.11). ACLAX was incepted earlier than MVCAX: ACLAX (22 years) vs MVCAX (25 years). ACLAX (1.22) is less costly to investors than MVCAX (0.98). ACLAX is a more actively managed with annual turnover of: 62.00 vs. MVCAX (24.00). ACLAX (6%) and MVCAX (6%) have equivalent initial investment costs. MVCAX has a lower initial minimum investment than ACLAX: MVCAX (1000) vs ACLAX (2500). MVCAX annual gain was more profitable for investors over the last year : 9.45 vs. ACLAX (3.76). MVCAX return over 5 years is better than : 17.60 vs. ACLAX (-9.19).
ACLAXMVCAXACLAX / MVCAX
Total Expense Ratio1.220.97126%
Annual Report Gross Expense Ratio1.220.98124%
Fund Existence22 years25 years-
Gain YTD12.90213.13698%
Front Load6%6%100%
Min. Initial Investment25001000250%
Min. Initial Investment IRAN/AN/A-
Net Assets5.68B17.2B33%
Annual Yield % from dividends1.221.11110%
Returns for 1 year3.769.4540%
Returns for 3 years9.1820.0646%
Returns for 5 years-9.1917.60-52%
Returns for 10 years14.2682.5717%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PDS83.433.09
+3.85%
Precision Drilling Corp
SGC13.130.09
+0.69%
Superior Group of Companies
TAK16.49-0.07
-0.42%
Takeda Pharmaceutical Company Limited
INDV40.21-0.29
-0.72%
Indivior Pharmaceuticals Inc.
MBRX2.21-0.07
-3.07%
Moleculin Biotech Inc